Showing results (11-20 of 58) with videos related to
Sort By:
Pageof 6
Journal of Thrombosis and Thrombolysis|October 24, 2009
Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbitsDonglu Zhang, Kan He, Nirmala Raghavan, et al.Journal of Medicinal Chemistry|July 8, 2015
Structure-Based Design of Macrocyclic Coagulation Factor VIIa InhibitorsE Scott Priestley, Daniel L Cheney, Indawati DeLucca, et al.Thrombosis and Haemostasis|July 1, 2010
BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studiesPancras C Wong, Joseph M Luettgen, Alan R Rendina, et al.Journal of Thrombosis and Thrombolysis|February 27, 2007
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbitsPancras C Wong, Earl J Crain, Carol A Watson, et al.Journal of Cardiovascular Pharmacology|May 22, 2007
Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbitsPancras C Wong, Earl J Crain, Carol A Watson, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2008
Apixaban metabolism and pharmacokinetics after oral administration to humansNirmala Raghavan, Charles E Frost, Zhigang Yu, et al.Journal of Thrombosis and Haemostasis : JTH|November 9, 2021
Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbitsPancras C Wong, Earl J Crain, Jeffrey M Bozarth, et al.Bioorganic & Medicinal Chemistry Letters|April 18, 2015
Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitorsPeter W Glunz, Xuhong Cheng, Daniel L Cheney, et al.Journal of Medicinal Chemistry|March 26, 2016
Atropisomer Control in Macrocyclic Factor VIIa InhibitorsPeter W Glunz, Luciano Mueller, Daniel L Cheney, et al.Bioorganic & Medicinal Chemistry Letters|January 26, 2006
Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitorsMimi L Quan, Qi Han, John M Fevig, et al.Pageof 6